Docality.com Logo
 
Dr. Johnny  Kao  Md image

Dr. Johnny Kao Md

1000 Montauk Hwy
West Islip NY 11795
631 764-4047
Medical School: Mount Sinai School Of Medicine Of City University Of New York - 2000
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #:
NPI: 1639141476
Taxonomy Codes:
2085R0001X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Johnny Kao is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:77301 Description:Radiotherapy dose plan imrt Average Price:$6,177.00 Average Price Allowed
By Medicare:
$1,942.47
HCPCS Code:77418 Description:Radiation tx delivery imrt Average Price:$1,523.00 Average Price Allowed
By Medicare:
$460.82
HCPCS Code:77290 Description:Set radiation therapy field Average Price:$1,528.40 Average Price Allowed
By Medicare:
$516.92
HCPCS Code:77338 Description:Design mlc device for imrt Average Price:$1,433.00 Average Price Allowed
By Medicare:
$485.82
HCPCS Code:77301 Description:Radiotherapy dose plan imrt Average Price:$1,249.51 Average Price Allowed
By Medicare:
$435.48
HCPCS Code:99223 Description:Initial hospital care Average Price:$699.64 Average Price Allowed
By Medicare:
$217.64
HCPCS Code:77338 Description:Design mlc device for imrt Average Price:$701.40 Average Price Allowed
By Medicare:
$233.03
HCPCS Code:77295 Description:Set radiation therapy field Average Price:$713.00 Average Price Allowed
By Medicare:
$249.26
HCPCS Code:77413 Description:Radiation treatment delivery Average Price:$688.00 Average Price Allowed
By Medicare:
$233.47
HCPCS Code:77263 Description:Radiation therapy planning Average Price:$619.00 Average Price Allowed
By Medicare:
$176.43
HCPCS Code:77427 Description:Radiation tx management x5 Average Price:$603.00 Average Price Allowed
By Medicare:
$197.93
HCPCS Code:77280 Description:Set radiation therapy field Average Price:$558.00 Average Price Allowed
By Medicare:
$183.10
HCPCS Code:77427 Description:Radiation tx management x5 Average Price:$555.00 Average Price Allowed
By Medicare:
$180.38
HCPCS Code:77263 Description:Radiation therapy planning Average Price:$499.00 Average Price Allowed
By Medicare:
$161.81
HCPCS Code:77014 Description:Ct scan for therapy guide Average Price:$430.16 Average Price Allowed
By Medicare:
$98.71
HCPCS Code:99205 Description:Office/outpatient visit new Average Price:$491.00 Average Price Allowed
By Medicare:
$181.71
HCPCS Code:77334 Description:Radiation treatment aid(s) Average Price:$451.65 Average Price Allowed
By Medicare:
$145.40
HCPCS Code:77470 Description:Special radiation treatment Average Price:$340.38 Average Price Allowed
By Medicare:
$113.15
HCPCS Code:77332 Description:Radiation treatment aid(s) Average Price:$226.70 Average Price Allowed
By Medicare:
$61.84
HCPCS Code:77290 Description:Set radiation therapy field Average Price:$243.83 Average Price Allowed
By Medicare:
$84.52
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$218.08 Average Price Allowed
By Medicare:
$70.65
HCPCS Code:77300 Description:Radiation therapy dose plan Average Price:$210.00 Average Price Allowed
By Medicare:
$67.04
HCPCS Code:77334 Description:Radiation treatment aid(s) Average Price:$193.99 Average Price Allowed
By Medicare:
$66.93
HCPCS Code:77336 Description:Radiation physics consult Average Price:$154.00 Average Price Allowed
By Medicare:
$45.34
HCPCS Code:77321 Description:Special teletx port plan Average Price:$149.00 Average Price Allowed
By Medicare:
$51.56
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$150.73 Average Price Allowed
By Medicare:
$55.39
HCPCS Code:77331 Description:Special radiation dosimetry Average Price:$137.00 Average Price Allowed
By Medicare:
$47.46
HCPCS Code:77280 Description:Set radiation therapy field Average Price:$109.99 Average Price Allowed
By Medicare:
$38.01
HCPCS Code:77300 Description:Radiation therapy dose plan Average Price:$97.00 Average Price Allowed
By Medicare:
$33.91
HCPCS Code:77417 Description:Radiology port film(s) Average Price:$53.00 Average Price Allowed
By Medicare:
$17.40
HCPCS Code:77417 Description:Radiology port film(s) Average Price:$45.00 Average Price Allowed
By Medicare:
$14.04

HCPCS Code Definitions

77334
Treatment devices, design and construction; complex (irregular blocks, special shields, compensators, wedges, molds or casts)
77300
Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician
77332
Treatment devices, design and construction; simple (simple block, simple bolus)
77301
Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77295
3-dimensional radiotherapy plan, including dose-volume histograms
77290
Therapeutic radiology simulation-aided field setting; complex
77300
Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
77301
Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77321
Special teletherapy port plan, particles, hemibody, total body
77331
Special dosimetry (eg, TLD, microdosimetry) (specify), only when prescribed by the treating physician
77336
Continuing medical physics consultation, including assessment of treatment parameters, quality assurance of dose delivery, and review of patient treatment documentation in support of the radiation oncologist, reported per week of therapy
77334
Treatment devices, design and construction; complex (irregular blocks, special shields, compensators, wedges, molds or casts)
77338
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77263
Therapeutic radiology treatment planning; complex
77014
Computed tomography guidance for placement of radiation therapy fields
99205
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
77338
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77290
Therapeutic radiology simulation-aided field setting; complex
77417
Therapeutic radiology port film(s)
77427
Radiation treatment management, 5 treatments
77417
Therapeutic radiology port film(s)
77427
Radiation treatment management, 5 treatments
77470
Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)
77280
Therapeutic radiology simulation-aided field setting; simple
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
77280
Therapeutic radiology simulation-aided field setting; simple
77263
Therapeutic radiology treatment planning; complex
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1235204207
Pulmonary Disease
745
1205819117
Diagnostic Radiology
716
1306807904
Diagnostic Radiology
597
1053475673
Internal Medicine
568
1235164120
Gynecological Oncology
561
1972571610
Diagnostic Radiology
449
1619945342
Diagnostic Radiology
418
1932145760
Diagnostic Radiology
365
1093794901
Cardiovascular Disease (Cardiology)
310
1609835065
Diagnostic Radiology
285
*These referrals represent the top 10 that Dr. Kao has made to other doctors

Publications

Correction: Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation Oncology. - PloS one
[This corrects the article DOI: 10.1371/journal.pone.0124329.].
Esophagus and Contralateral Lung-Sparing IMRT for Locally Advanced Lung Cancer in the Community Hospital Setting. - Frontiers in oncology
The optimal technique for performing lung IMRT remains poorly defined. We hypothesize that improved dose distributions associated with normal tissue-sparing IMRT can allow safe dose escalation resulting in decreased acute and late toxicity.We performed a retrospective analysis of 82 consecutive lung cancer patients treated with curative intent from 1/10 to 9/14. From 1/10 to 4/12, 44 patients were treated with the community standard of three-dimensional conformal radiotherapy or IMRT without specific esophagus or contralateral lung constraints (standard RT). From 5/12 to 9/14, 38 patients were treated with normal tissue-sparing IMRT with selective sparing of contralateral lung and esophagus. The study endpoints were dosimetry, toxicity, and overall survival.Despite higher mean prescribed radiation doses in the normal tissue-sparing IMRT cohort (64.5 vs. 60.8 Gy, p = 0.04), patients treated with normal tissue-sparing IMRT had significantly lower lung V20, V10, V5, mean lung, esophageal V60, and mean esophagus doses compared to patients treated with standard RT (p ≤ 0.001). Patients in the normal tissue-sparing IMRT group had reduced acute grade ≥3 esophagitis (0 vs. 11%, p < 0.001), acute grade ≥2 weight loss (2 vs. 16%, p = 0.04), and late grade ≥2 pneumonitis (7 vs. 21%, p = 0.02). The 2-year overall survival was 52% with normal tissue-sparing IMRT arm compared to 28% for standard RT (p = 0.015).These data provide proof of principle that suboptimal radiation dose distributions are associated with significant acute and late lung and esophageal toxicity that may result in hospitalization or even premature mortality. Strict attention to contralateral lung and esophageal dose-volume constraints are feasible in the community hospital setting without sacrificing disease control.
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. - Clinical cancer research : an official journal of the American Association for Cancer Research
The clinical effects of sunitinib on human myeloid-derived suppressor cell (MDSC) subsets and correlation of the T-cell-mediated immune responses and clinical outcomes in patients with oligometastases treated by stereotactic body radiotherapy (SBRT) have been evaluated.The numbers of granulocytic and monocytic MDSC subsets, effector T cells, and regulatory T cells in the peripheral blood were evaluated pre- and post-sunitinib treatment and concurrent with SBRT. Correlations between MDSC, Treg, and T-cell responses and clinical outcomes were analyzed.Patients with oligometastases of various cancer types had elevated granulocytic MDSC and certain subsets of monocytic MDSC population. Sunitinib treatment resulted in a significant reduction in monocytic MDSC, phosphorylated STAT3, and arginase levels in monocytic MDSC (CD33(+)CD14(+)CD16(+)), and an increase in T-cell proliferative activity in cancer patients. Interestingly, the effects of sunitinib on reducing the accumulation and immune-suppressive function of MDSC were significantly correlated with Treg reduction, in responders but not in nonresponding patients. SBRT synergized the therapeutic effects of sunitinib, especially as related to decreased numbers of monocytic MDSC, Treg, and B cells, and augmented Tbet expression in primary CD4 and CD8 T cells. These effects were not observed in patients receiving radiation therapy alone. Most interestingly, the responders, defined by sunitinib-mediated reduction in CD33(+)CD11b(+) myeloid cell populations, tend to exhibit improved progression-free survival and cause-specific survival.Sunitinib treatment increased the efficacy of SBRT in patients with oligometastases by reversing MDSC and Treg-mediated immune suppression and may enhance cancer immune therapy to prevent tumor recurrence post-SBRT.©2015 American Association for Cancer Research.
Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation Oncology. - PloS one
There is an urgent need for a robust, clinically useful predictive model for survival in a heterogeneous group of patients with metastatic cancer referred to radiation oncology.From May 2012 to August 2013, 143 consecutive patients with stage IV cancer were prospectively evaluated by a single radiation oncologist. We retrospectively analyzed the effect of 29 patient, laboratory and tumor-related prognostic factors on overall survival using univariate analysis. Variables that were statistically significant on univariate analysis were entered into a multivariable Cox regression to identify independent predictors of overall survival.The median overall survival was 5.5 months. Four prognostic factors significantly predicted survival on multivariable analysis including ECOG performance status (0-1 vs. 2 vs. 3-4), number of active tumors (1 to 5 vs. ≥ 6), albumin levels (≥ 3.4 vs. 2.4 to 3.3 vs. < 2.4 and primary tumor site (Breast, Kidney or Prostate vs. Other). Risk group stratification was performed by assigning points for adverse prognostic factors resulting in very low, low, intermediate and high risk groups. The median survival was > 31.4 months for very low risk patients compared to 14.5 months for low risk, 4.1 months for intermediate risk and 1.2 months for high risk (p < 0.001).These data suggest that a model that considers performance status, extent of disease, primary tumor site and serum albumin represents a simple model to accurately predict survival for patients with stage IV cancer who are potential candidates for radiation therapy.
Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. - Cancer research
While viral antigens in human papillomavirus (HPV)-related oropharyngeal cancer (HPVOPC) are attractive targets for immunotherapy, the effects of existing standard-of-care therapies on immune responses to HPV are poorly understood. We serially sampled blood from patients with stage III-IV oropharyngeal cancer undergoing concomitant chemoradiotherapy with or without induction chemotherapy. Circulating immunocytes including CD4(+) and CD8(+) T cells, regulatory T cells (Treg), and myeloid-derived suppressor cells (MDSC) were profiled by flow cytometry. Antigen-specific T-cell responses were measured in response to HPV16 E6 and E7 peptide pools. The role of PD-1 signaling in treatment-related immunosuppression was functionally defined by performing HPV-specific T-cell assays in the presence of blocking antibody. While HPV-specific T-cell responses were present in 13 of 18 patients before treatment, 10 of 13 patients lost these responses within 3 months after chemoradiotherapy. Chemoradiotherapy decreased circulating T cells and markedly elevated MDSCs. PD-1 expression on CD4(+) T cells increased by nearly 2.5-fold after chemoradiotherapy, and ex vivo culture with PD-1-blocking antibody enhanced HPV-specific T-cell responses in 8 of 18 samples tested. Chemoradiotherapy suppresses circulating immune responses in patients with HPVOPC by unfavorably altering effector:suppressor immunocyte ratios and upregulating PD-1 expression on CD4(+) T cells. These data strongly support testing of PD-1-blocking agents in combination with standard-of-care chemoradiotherapy for HPVOPC.©2014 American Association for Cancer Research.
Tumor Directed, Scalp Sparing Intensity Modulated Whole Brain Radiotherapy for Brain Metastases. - Technology in cancer research & treatment
Despite significant technical advances in radiation delivery, conventional whole brain radiation therapy (WBRT) has not materially changed in the past 50 years. We hypothesized that IMRT can selectively spare uninvolved brain and scalp with the goal of reducing acute and late toxicity. MRI/CT simulation image registration was performed. We performed IMRT planning to simultaneously treat the brain tumor(s) on MRI + 5 mm margin to 37.5 Gy in 15 fractions while limiting the uninvolved brain + 2 mm margin to 30 Gy in 15 fractions and the mean scalp dose to #18 Gy. Three field IMRT plans were compared to conventional WBRT plans. Symptomatic patients were started on conventional WBRT for 2 to 3 fractions while IMRT planning was performed. Seventeen consecutive patients with brain metastases with RPA class I and II disease with no leptomeningeal spread were treated with IMRT WBRT. Compared to conventional WBRT, IMRT reduced the mean scalp dose (26.2 Gy vs. 16.4 Gy, p < 0.001) and the mean PTV30 dose (38.4 Gy vs. 32.0 Gy, p < 0.001) while achieving similar mean PTV37.5 doses (38.3 Gy vs. 38.0 Gy, p = 0.26). Using Olsen hair loss score criteria, 4 of 15 assessable patients preserved at least 50% of hair coverage at 1 to 3 months after treatment while 6 patients preserved between 25 and 50% hair coverage. At a median follow-up of 6.8 months (range: 5 to 15 months), the median overall survival was 5.4 months. Four patients relapsed within the brain, one within the PTV37.5 and three outside the PTV37.5. Tumor directed, scalp sparing IMRT is feasible, achieves rational dose distributions and preserves partial hair coverage in the majority of patients. Further studies are warranted to determine whether the increased utilization of resources needed for IMRT are appropriate in this setting.© The Author(s) 2014.
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. - Targeted oncology
Preliminary results demonstrated that concurrent sunitinib and stereotactic body radiation therapy (SBRT) is an active regimen for metastases limited in number and extent. This analysis was conducted to determine the long-term survival and cancer control outcomes for this novel regimen. Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010. The majority of patients were treated with 37.5 mg sunitinib (days 1-28) and SBRT 50 Gy (days 8-12 and 15-19) and maintenance sunitinib was used in 39 % of patients. Median follow up for surviving patients is 3.6 years. The 4-year estimates for local control, distant control, progression-free and overall survival were 75 %, 40 %, 34 % and 29 %, respectively. At last follow-up, 26 % of patients were alive without evidence of disease, 7 % were alive with distant metastases, 48 % died from distant metastases, 2 % died from local progression, 13 % died from comorbid illness, and 4 % died from treatment-related toxicities. Patients with kidney and prostate primary tumors were associated with a significantly improved overall survival (hazard ratio = 0.25, p = 0.04). Concurrent sunitinib and SBRT is a promising approach for the treatment of oligometastases and further study of this novel combination is warranted.
Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy. - Experimental and therapeutic medicine
Radiation with or without chemotherapy is considered the mainstay of treatment for the majority of patients with oropharyngeal cancer. The goal of this study was to analyze competing causes of mortality in patients with oropharyngeal cancer with long-term follow-up. We queried the Surveillance, Epidemiology and End Results (SEER) database and identified 3728 patients with oropharyngeal cancer treated between 1988 and 2001 with definitive radiotherapy. We analyzed predictors of overall survival and risks of mortality from index oropharyngeal cancer, second primary cancer, cardiovascular disease and other causes using a cumulative incidence analysis and Cox multivariate analysis. With a median follow-up of 6.8 years, the 5- and 10-year overall survival was 37 and 22%, respectively. At 5 years, the risk of mortality from primary oropharyngeal cancer was 35%. Between years 3 and 10, 69% of mortalities were attributed to causes other than the index cancer. Despite advances in the non-surgical treatment of oropharyngeal cancer, patients remain at significant risk of cancer- and non-cancer-related mortality.
γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers. - PloS one
Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells.DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model.We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity.MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase.
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. - PloS one
Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases.Twenty five patients with oligometastases, defined as 1-5 sites of active disease on whole body imaging, were enrolled in a phase II trial from 2/08 to 9/10. The most common tumor types treated were head and neck, liver, lung, kidney and prostate cancers. Patients were treated with the recommended phase II dose of 37.5 mg daily sunitinib (days 1-28) and IGRT 50 Gy (days 8-12 and 15-19). Maintenance sunitinib was used in 33% of patients. Median follow up was 17.5 months (range, 0.7 to 37.4 months).The 18-month local control, distant control, progression-free survival (PFS) and overall survival (OS) were 75%, 52%, 56% and 71%, respectively. At last follow-up, 11 (44%) patients were alive without evidence of disease, 7 (28%) were alive with distant metastases, 3 (12%) were dead from distant metastases, 3 (12%) were dead from comorbid illness, and 1 (4%) was dead from treatment-related toxicities. The incidence of acute grade ≥ 3 toxicities was 28%, most commonly myelosuppression, bleeding and abnormal liver function tests.Concurrent sunitinib and IGRT achieves major clinical responses in a subset of patients with oligometastases.ClinicalTrials.gov NCT00463060.

Map & Directions

1000 Montauk Hwy West Islip, NY 11795
View Directions In Google Maps

Nearby Doctors

435 Montauk Hwy
West Islip, NY 11795
631 224-4545
400 Montauk Hwy Suite 111
West Islip, NY 11795
631 695-5440
1000 Montauk Hwy
West Islip, NY 11795
631 764-4089
754 Montauk Hwy
West Islip, NY 11795
631 220-0909
1000 Montauk Hwy
West Islip, NY 11795
631 763-3000
1000 Montauk Hwy
West Islip, NY 11795
952 951-1100
434 Sunrise Hwy
West Islip, NY 11795
631 761-1499
1000 Montauk Hwy
West Islip, NY 11795
631 764-4444
1000 Montauk Hwy
West Islip, NY 11795
631 764-4163